Literature DB >> 16570203

Short-term outcomes of severe lupus nephritis in a cohort of predominantly African-American children.

Keith K Lau1, Deborah P Jones, Margaret C Hastings, Lillian W Gaber, Bettina H Ault.   

Abstract

Renal involvement is one of the major determinants of the outcome in patients with systemic lupus erythematosus. Although African-American ethnicity has been suggested to be a poor prognostic factor in severe lupus nephritis in adult patients, information on outcomes of African-American children with this disease is still very limited. We retrospectively studied the patients diagnosed with severe lupus nephritis by renal biopsy at Le Bonheur Children's Medical Center from January 1990 to December 2003. All patients were below the age of 18 years at the time of biopsy. Clinical features assessed included age, gender, race, estimated glomerular filtration rate (GFR), presence of hypertension, gross hematuria, degree of proteinuria, complement 3 and 4 levels, serum albumin, renal histology and dose of oral prednisone. Forty-four patients were studied: 82% were African-American and 89% were female. Mean age at biopsy was 14.2+/-3 years (median 15.0 years; range 4.7 years to 17.0 years). Renal biopsies were assessed according to the WHO classification. Twenty-seven percent, 43%, and 30% were in class III, IV and V, respectively. At presentation, 55% had hypertension and 23% had a history of macroscopic hematuria. The patients had varying degrees of proteinuria, including 18% with nephrotic syndrome. Eighteen percent had moderate renal insufficiency with estimated GFRs less than 50 ml/1.73 m2 body surface area per minute. All the patients were treated with corticosteroids. Sixty-eight percent also received cyclophosphamide and 20% received either mycophenolate mofetil (MMF) or azathioprine (AZA). Two patients developed end stage renal disease and required chronic dialysis within 12 months of biopsy. At the 12-month follow-up visit, 23% of patients had complete remission and 48% had partial remission. The mean estimated GFR had increased from 96.0 ml/1.73 m2 per minute to 124 ml/1.73 m2 per minute (P=0.03). Mean serum creatinine levels decreased from 1.62 mg/dl to 0.91 mg/dl (P=0.03). Complement 3 levels increased from 54.3 mg/dl to 90.3 mg/dl (P<0.01). Mean serum albumin levels also increased from 2.8 mg/dl to 3.6 mg/dl (P<0.01) and urine protein-to-creatinine ratio decreased from 5.8 to 1.0 (P<0.01). The average prednisone dose decreased from 0.96 mg/kg per day to 0.41 mg/kg per day (P=0.64). In our center, with predominantly African-American children, patients with lupus nephritis presented similarly to those in other studies with predominantly Caucasian patients, and short-term renal outcomes were not different.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16570203     DOI: 10.1007/s00467-006-0060-3

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  34 in total

1.  Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.

Authors:  Tak-Mao Chan; Kai-Chung Tse; Colin Siu-On Tang; Mo-Yin Mok; Fu-Keung Li
Journal:  J Am Soc Nephrol       Date:  2005-02-23       Impact factor: 10.121

2.  Lupus nephritis in children: prognostic significance of clinicopathological findings.

Authors:  S Emre; I Bilge; A Sirin; I Kilicaslan; A Nayir; F Oktem; V Uysal
Journal:  Nephron       Date:  2001-02       Impact factor: 2.847

Review 3.  Treatment of lupus nephritis in children.

Authors:  P Niaudet
Journal:  Pediatr Nephrol       Date:  2000-02       Impact factor: 3.714

4.  A 10 year review of systemic lupus erythematosus in Singapore children.

Authors:  B W Lee; H K Yap; W C Yip; P S Low; A H Saw; J S Tay; H B Wong
Journal:  Aust Paediatr J       Date:  1987-06

5.  Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents.

Authors: 
Journal:  Pediatrics       Date:  1996-10       Impact factor: 7.124

6.  Childhood-onset lupus nephritis: a single-center experience of pulse intravenous cyclophosphamide therapy.

Authors:  Giancarlo Barbano; Rosanna Gusmano; Beatrice Damasio; Maria Giannina Alpigiani; Antonella Buoncompagni; Marco Gattorno; Francesco Perfumo
Journal:  J Nephrol       Date:  2002 Mar-Apr       Impact factor: 3.902

7.  Initial presentation of childhood-onset systemic lupus erythematosus: a French multicenter study.

Authors:  B Bader-Meunier; J B Armengaud; E Haddad; R Salomon; G Deschênes; I Koné-Paut; T Leblanc; C Loirat; P Niaudet; J C Piette; A M Prieur; P Quartier; F Bouissou; M Foulard; G Leverger; I Lemelle; P Pilet; M Rodière; N Sirvent; P Cochat
Journal:  J Pediatr       Date:  2005-05       Impact factor: 4.406

8.  Renal pathology and long-term outcome in childhood SLE.

Authors:  A Sumboonnanonda; A Vongjirad; V Suntornpoch; T Laohapand; P Parichatikanond
Journal:  J Med Assoc Thai       Date:  1998-11

9.  Lupus nephritis: prognostic factors in children.

Authors:  D K McCurdy; T J Lehman; B Bernstein; V Hanson; K K King; R Nadorra; B H Landing
Journal:  Pediatrics       Date:  1992-02       Impact factor: 7.124

10.  Lupus nephritis in children: a longitudinal study of prognostic factors and therapy.

Authors:  N Baqi; S Moazami; A Singh; H Ahmad; S Balachandra; A Tejani
Journal:  J Am Soc Nephrol       Date:  1996-06       Impact factor: 10.121

View more
  16 in total

1.  Clinical presentation and outcomes of childhood-onset membranous lupus nephritis.

Authors:  Maria Pereira; Eyal Muscal; Karen Eldin; M John Hicks; Anna Carmela P Sagcal-Gironella; Marietta DeGuzman; Scott E Wenderfer
Journal:  Pediatr Nephrol       Date:  2017-07-17       Impact factor: 3.714

Review 2.  Prevalence and burden of pediatric-onset systemic lupus erythematosus.

Authors:  Sylvia Kamphuis; Earl D Silverman
Journal:  Nat Rev Rheumatol       Date:  2010-08-03       Impact factor: 20.543

Review 3.  Can mycophenolate mofetil substitute cyclophosphamide treatment of pediatric lupus nephritis?

Authors:  Ana Paredes
Journal:  Pediatr Nephrol       Date:  2007-03-17       Impact factor: 3.714

4.  Three decades of progress in treating childhood-onset lupus nephritis.

Authors:  Tanya Pereira; Carolyn L Abitbol; Wacharee Seeherunvong; Chryso Katsoufis; Jayanthi Chandar; Michael Freundlich; Gastón Zilleruelo
Journal:  Clin J Am Soc Nephrol       Date:  2011-07-28       Impact factor: 8.237

5.  A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome.

Authors:  Shuichiro Fujinaga; Yoshiyuki Ohtomo; Daisuke Umino; Mayako Takemoto; Toshiaki Shimizu; Yuichiro Yamashiro; Kazunari Kaneko
Journal:  Pediatr Nephrol       Date:  2006-11-04       Impact factor: 3.714

6.  Childhood-onset systemic lupus erythematosus.

Authors:  Wasiu Olowu
Journal:  J Natl Med Assoc       Date:  2007-07       Impact factor: 1.798

7.  Predictors of relapse and end stage kidney disease in proliferative lupus nephritis: focus on children, adolescents, and young adults.

Authors:  Keisha L Gibson; Debbie S Gipson; Susan A Massengill; Mary Anne Dooley; William A Primack; Maria A Ferris; Susan L Hogan
Journal:  Clin J Am Soc Nephrol       Date:  2009-10-09       Impact factor: 8.237

8.  Clinical characteristics of children with membranous lupus nephritis: the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry.

Authors:  A Boneparth; S E Wenderfer; L Nandini Moorthy; S M Radhakrishna; A C P Sagcal-Gironella; E von Scheven
Journal:  Lupus       Date:  2016-08-20       Impact factor: 2.911

Review 9.  Membranous nephropathy: not just a disease for adults.

Authors:  Rivka Ayalon; Laurence H Beck
Journal:  Pediatr Nephrol       Date:  2013-12-29       Impact factor: 3.714

10.  Mycophenolate mofetil in the treatment of lupus nephritis.

Authors:  Patrick Fk Yong; David P D'Cruz
Journal:  Biologics       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.